Skip to main content
PolicySpeak
← All files
NNS

Novo Nordisk A/S

Company · Denmark · EU Transparency Register 29570313329-11

5
positions filed
in the 326 files tracked
3
legislative files
of 326 tracked
3
with a full position paper
attached to a submission

Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.

Who they are

Among the 925 companies & groups on this site, they rank #234 by legislative files engaged — a count of participation, not a measure of influence.

3.5
declared lobbying FTE
self-declared
€2M+
declared costs / yr (floor)
1
EP accreditations
as declared to the register
2010
in the register since

Declares membership of

  • Novo Nordisk is a member of:
  • EFPIA →
  • The Danish Chamber of Commerce
  • The Confederation of Danish Industries
  • EUCOPE
  • Science|Business

Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).

Register category
Companies & groups
Head office
Bagsværd, Denmark

Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.

Track Novo in PolicySpeak: request access →

Work at Novo Nordisk A/S? so we know who speaks for it.

Follow the files Novo Nordisk A/S engages with

One email on Tuesdays when a new position is filed on these 3 files, from Novo Nordisk A/S or from anyone else on them. Only when there is something new.

We use your email for these updates, and PolicySpeak may contact you about the product. Unsubscribe in one click. Privacy policy.

Their record over time

Novo Nordisk A/S filed 5 positions between 11 Jun 2025 and 5 Aug 2026, across 3 of the 326 legislative files tracked here, attaching a full position paper 3 times.

2025 · 2 filed2026 · 3 filed

What they argued

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 30 Jun 2026PDFsource

We thank the Commission for the possibility to provide feedback on the targeted revision of the MDR/IVDR. We fully support the initiative to streamline and simplify the regulatory framework while preserving a high level of public health and patient safety. Please find our comments in the attached file.

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 6 Oct 2025PDFsource

Novo Nordisk appreciates the opportunity to provide feedback to the call for evidence on the targeted revision of the EU rules for medical devices and in vitro diagnostics. We support the initiative to streamline and future-proof the regulatory framework while preserving a high level of public health and patient safety.

European Biotech Actfiled 5 Aug 2026source

Europes competitiveness has taken a serious hit in the recent years, particularly in biotechnology. The EU Biotech Act I is a positive step towards strengthening the European biotechnology ecosystem with measures to accelerate clinical trials, reduce regulatory complexity and incentiv-ise innovation in Europe all improving patient access to best-in-class medicines.

European Biotech Actfiled 11 Jun 2025source

Novo Nordisk A/S welcomes the European Commission's (EC) initiative to develop a Biotechnology and Biomanufacturing Act, aiming to transform Europe from being a regulatory leader to a global champion of biotechnology innovation.

Health Checks for Cardiovascular diseasesfiled 16 May 2026PDFsource

Novo Nordisk supports strengthening early detection and action on cardiovascular disease (CVD) across the EU through systematic cardiometabolic health checks that explicitly include the major chronic conditions driving risk - i.e. obesity and type 2 diabetes (T2D).

Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.

Turns up on the same files

Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.

Showing 5 of 64.

Is this your organization?

Everything on this page comes from Novo Nordisk A/S’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.

Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.